Your browser doesn't support javascript.
loading
Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial.
Berard, Jason A; Freedman, Mark S; Marrie, Ruth Ann; Marriott, James J; Atkins, Harold L; Szwajcer, David; Courtman, David W; Thebault, Simon; Walker, Lisa A S.
Afiliación
  • Berard JA; The Ottawa Hospital Research Institute, Ottawa, Canada; The University of Ottawa Brain and Mind Research Institute, Ottawa, Canada. Electronic address: jberard@ohri.ca.
  • Freedman MS; The Ottawa Hospital Research Institute, Ottawa, Canada; The University of Ottawa Brain and Mind Research Institute, Ottawa, Canada; University of Ottawa, Department of Medicine, Ottawa, Canada.
  • Marrie RA; Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
  • Marriott JJ; Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
  • Atkins HL; The Ottawa Hospital Research Institute, Ottawa, Canada; The University of Ottawa Brain and Mind Research Institute, Ottawa, Canada; University of Ottawa, Department of Medicine, Ottawa, Canada.
  • Szwajcer D; Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
  • Courtman DW; The Ottawa Hospital Research Institute, Ottawa, Canada; University of Ottawa, Department of Medicine, Ottawa, Canada.
  • Thebault S; The Ottawa Hospital Research Institute, Ottawa, Canada; University of Ottawa, Department of Medicine, Ottawa, Canada.
  • Walker LAS; The Ottawa Hospital Research Institute, Ottawa, Canada; The University of Ottawa Brain and Mind Research Institute, Ottawa, Canada; University of Ottawa, Department of Medicine, Ottawa, Canada; Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada; C
Mult Scler Relat Disord ; 61: 103779, 2022 May.
Article en En | MEDLINE | ID: mdl-35367874
BACKGROUND: Mesenchymal stem cell (MSC) therapies are being evaluated in multiple sclerosis (MS) for possible neural repair. To date, the potential benefits on cognition have received little attention. The objective of the current study was to comprehensively evaluate cognition before and after MSC therapy in those with MS as part of a double-blind, phase II clinical trial. METHODS: Twenty-eight individuals with a confirmed diagnosis of MS were randomly assigned into two study arms. Cognition was evaluated using an expanded Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery. The battery was administered at Week 0, Week 24, and Week 48 and results were analysed at the group and individual level. RESULTS: No detectable effect of MSC-mediated neural repair was noted in the short-term with respect to cognition, although some cognitive stability or improvement was observed. Decline was noted in some cognitive areas immediately following the procedure at Week 24; though these were temporary with performance returning to baseline levels at Week 48. CONCLUSIONS: While MSC therapy does not lead to improvement in cognition, at least in the short-term, neither does the procedure have lasting deleterious effects. The current findings lend support to the safety and feasibility of MSC therapy as a potentially viable treatment option for individuals with MS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas / Esclerosis Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Humans Idioma: En Revista: Mult Scler Relat Disord Año: 2022 Tipo del documento: Article Pais de publicación: Países Bajos